Weight Management
Tirzepatide
Tirzepatide: read about Zepbound's approved uses, clinical evidence, safety warnings, oral contraceptive interactions, and prescribing questions.
At a glance
Tirzepatide: read about Zepbound's approved uses, clinical evidence, safety warnings, oral contraceptive interactions, and prescribing questions.
What is tirzepatide?
Tirzepatide activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It can reduce appetite and food intake and affect glucose regulation. A dual mechanism does not by itself prove that it is the best choice for any particular person.
This guide focuses on Zepbound injection. Approval is specific to the product and indication, not a blanket approval of all products sold as tirzepatide. Decisions about eligibility and monitoring belong with a qualified prescriber who knows the patient's history.
Sources: [zepbound-label]
Zepbound's approved uses
The cited label covers reducing excess body weight and maintaining weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related condition. It is used with a reduced-calorie diet and increased physical activity.
Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. That indication is not approval for every type of sleep problem or for people without obesity. A diagnosis and follow-up are important; do not stop prescribed positive airway pressure treatment based on this article.
Sources: [zepbound-label] [osa-approval]
Clinical evidence and its limits
The Zepbound prescribing information summarizes controlled weight-management trials and their eligibility criteria, treatment groups and adverse events. Results from a supervised clinical trial should not be treated as a guaranteed result for every person or for a compounded formulation.
For the sleep-apnea indication, FDA cited two randomized, double-blind, placebo-controlled studies involving 469 adults without type 2 diabetes over 52 weeks. One study included people using positive airway pressure, and the other included people unable or unwilling to use it.
Tirzepatide reduced the apnea-hypopnea index, a measure of breathing disruptions per hour of sleep, compared with placebo. FDA noted that the improvement was likely related to body-weight reduction. These results apply to the studied population and do not establish a universal cure for sleep apnea.
Sources: [zepbound-label] [osa-approval]
Important warnings and contraindications
Zepbound carries a boxed warning about thyroid C-cell tumors in rats; relevance to humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a serious hypersensitivity to the product.
Common adverse reactions include nausea, vomiting, diarrhea, constipation, abdominal pain and other gastrointestinal symptoms. The label warns about severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis, serious allergic reactions, and diabetic retinopathy complications. It is not recommended in severe gastroparesis.
Pregnancy and pregnancy plans require discussion with a clinician; the label warns of potential fetal harm and directs discontinuation when pregnancy is recognized. Tell healthcare professionals about treatment before anesthesia or deep sedation because of the risk of pulmonary aspiration. This summary is not a substitute for the full safety information.
Sources: [zepbound-label]
Interactions, including oral contraception
Delayed gastric emptying can affect absorption of oral medicines. The label advises patients using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. Discuss the plan with the prescriber before starting treatment.
Insulin or medicines that stimulate insulin secretion can increase the risk of hypoglycemia. Do not adjust those medicines independently. The label advises against combining Zepbound with other tirzepatide products or any GLP-1 receptor agonist.
Sources: [zepbound-label]
What to discuss before treatment
Zepbound injection uses a weekly, product-specific escalation schedule. The appropriate dose depends on indication, response and tolerability; this guide does not provide an individual dosing plan or instructions for preparing injections.
Ask about the exact dispensed product, contraindications, interactions, monitoring, missed doses and symptoms that need urgent attention. FDA identifies concerns with unapproved GLP-1 drugs and reports dosing errors and adverse events. A compounded product is not FDA-approved or automatically equivalent to the approved product.
Sources: [zepbound-label] [compounding]
Frequently asked questions
These FAQs use the sources listed below. They are not independently clinically reviewed.
How does tirzepatide compare to semaglutide?
Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors. That difference alone cannot predict an individual's response. Compare the evidence for the exact product and indication with a prescriber, not only averages from separate studies.
Sources: [zepbound-label] [wegovy-label]
Is tirzepatide FDA approved?
Zepbound is an FDA-approved tirzepatide product for specified weight-management and sleep-apnea indications. This is not blanket approval for every tirzepatide preparation, including compounded products.
Sources: [zepbound-label] [compounding]
Sources and reading notes
Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.
[zepbound-label] U.S. Food and Drug Administration — Zepbound injection prescribing information (January 2026)
Product-specific indications and safety information. Consult the current label with your prescriber.
[osa-approval] U.S. Food and Drug Administration — FDA approves first medication for obstructive sleep apnea (December 2024)
[compounding] U.S. Food and Drug Administration — FDA concerns with unapproved GLP-1 drugs used for weight loss
[wegovy-label] U.S. Food and Drug Administration — Wegovy injection prescribing information (August 2025)
Product-specific indications, contraindications, interactions and clinical studies. Consult the current label with your prescriber.
About this entry
Article updated: .
AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.